OM:FLUI

Stock Analysis Report

Executive Summary

Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Share Price & News

How has Fluicell's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.6%

FLUI

2.7%

SE Medical Equipment

2.7%

SE Market


1 Year Return

-27.2%

FLUI

29.2%

SE Medical Equipment

10.0%

SE Market

Return vs Industry: FLUI underperformed the Swedish Medical Equipment industry which returned 29.2% over the past year.

Return vs Market: FLUI underperformed the Swedish Market which returned 10% over the past year.


Shareholder returns

FLUIIndustryMarket
7 Day-4.6%2.7%2.7%
30 Day-7.2%-0.4%1.9%
90 Day5.1%-1.4%3.2%
1 Year-27.2%-27.2%30.6%29.2%14.7%10.0%
3 Yearn/a48.0%30.5%31.1%11.4%
5 Yearn/a67.9%40.1%61.5%27.2%

Price Volatility Vs. Market

How volatile is Fluicell's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Fluicell undervalued compared to its fair value and its price relative to the market?

3.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate FLUI's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate FLUI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FLUI is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: FLUI is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate FLUI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FLUI is good value based on its PB Ratio (3.8x) compared to the SE Medical Equipment industry average (4.5x).


Next Steps

Future Growth

How is Fluicell forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Fluicell has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Fluicell performed over the past 5 years?

-34.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: FLUI is unprofitable, and losses have increased over the past 5 years at a rate of -34.2% per year.

Accelerating Growth: Unable to compare FLUI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FLUI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.3%).


Return on Equity

High ROE: FLUI has a negative Return on Equity (-115.56%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: FLUI is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: FLUI is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Fluicell's financial position?


Financial Position Analysis

Short Term Liabilities: FLUI's short term assets (SEK15.2M) exceeds its short term liabilities (SEK2.7M)

Long Term Liabilities: FLUI has no long term liabilities


Debt to Equity History and Analysis

Debt Level: FLUI is debt free.

Reducing Debt: FLUI had no debt 5 years ago.


Balance Sheet

Inventory Level: FLUI has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if FLUI's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FLUI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: FLUI has less than a year of cash runway if free cash flow continues to reduce at historical rates of -47% each year


Next Steps

Dividend

What is Fluicell's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate FLUI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate FLUI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if FLUI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FLUI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FLUI's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of Fluicell's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Victoire Viannay (44yo)

2.8yrs

Tenure

0

Ms. Victoire Viannay has been Chief Executive Officer at Fluicell AB (publ) since 2017. Previously, Ms. Viannay served as the Chief Operating Officer of Fluicell AB. Former Legal & HR Assistant Manager at  ...


Management Age and Tenure

2.8yrs

Average Tenure

44yo

Average Age

Experienced Management: FLUI's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

3.8yrs

Average Tenure

47yo

Average Age

Experienced Board: FLUI's board of directors are considered experienced (3.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Mats Jonasson (63yo)

    Chief Financial Officer

    • Tenure: 3.8yrs
  • Gavin D. Jeffries (39yo)

    CTO & Director

    • Tenure: 7.8yrs
  • Victoire Viannay (44yo)

    Chief Executive Officer

    • Tenure: 2.8yrs
  • Tatsiana Lobovkina (44yo)

    Chief Scientific Officer

    • Tenure: 1.8yrs

Board Members

  • Owe Orwar (55yo)

    Director

    • Tenure: 4.8yrs
  • Stefan Tilk (55yo)

    Chairman of the Board

    • Tenure: 3.8yrs
  • Carl Fhager (44yo)

    Director

    • Tenure: 2.8yrs
  • Gavin D. Jeffries (39yo)

    CTO & Director

    • Tenure: 7.8yrs
  • Daniel Chiu (47yo)

    Director

    • Tenure: 2.8yrs

Company Information

Fluicell AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fluicell AB (publ)
  • Ticker: FLUI
  • Exchange: OM
  • Founded: 2012
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr55.538m
  • Shares outstanding: 7.48m
  • Website: https://www.fluicell.com

Location

  • Fluicell AB (publ)
  • Biotech-Huset, vån 7
  • Arvid Wallgrens Backe 20
  • Gothenburg
  • Västra Götaland County
  • 413 46
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FLUIOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKApr 2018

Biography

Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems f ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 22:08
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.